Cefiderocol for Burn Injuries
What You Need to Know Before You Apply
What is the purpose of this trial?
Cefiderocol is a powerful, broad spectrum antibiotic approved to treat hospital-acquired or ventilator associated pneumonia and urinary tract infections. Although cefiderocol has labeled dosing recommendations, including augmented renal clearance, patients with burn injury remain an unstudied population at high risk for MDR pathogens. The primary objective of this study is to evaluate the pharmacokinetic principles of cefiderocol in patients after acute burn injury. Findings from this study will determine the dose and interval necessary to maintain therapeutic concentrations of cefiderocol in patients after burn injury for adequate bactericidal activity, prevention of resistance, and treatment outcomes.
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Patients receive cefiderocol and undergo pharmacokinetic sampling
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Cefiderocol
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Patients receiving cefiderocol
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Tennessee
Lead Sponsor
Shionogi Inc.
Industry Sponsor
Regional Medical Center, Regional One Health
Collaborator
Center for Anti-Infective Research and Development
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.